High-Dose Vitamin B3 Shows Early Promise Against Glioblastoma in Small Trial

High-dose vitamin B3 (niacin) is showing intriguing early promise as an addition to standard glioblastoma treatment. In a small clinical trial, 82% of patients remained progression-free after six months, suggesting it may help revive immune cells suppressed by the aggressive brain cancer. Larger studies are needed to confirm these preliminary findings.